These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 30284618

  • 1. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
    Marchand L, Thivolet A, Dalle S, Chikh K, Reffet S, Vouillarmet J, Fabien N, Cugnet-Anceau C, Thivolet C.
    Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
    [Abstract] [Full Text] [Related]

  • 2. The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors.
    Marchand L, Disse E, Dalle S, Reffet S, Vouillarmet J, Fabien N, Thivolet C, Cugnet-Anceau C.
    Acta Diabetol; 2019 Dec; 56(12):1239-1245. PubMed ID: 31423559
    [Abstract] [Full Text] [Related]

  • 3. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
    Sun X, Roudi R, Dai T, Chen S, Fan B, Li H, Zhou Y, Zhou M, Zhu B, Yin C, Li B, Li X.
    BMC Cancer; 2019 Jun 10; 19(1):558. PubMed ID: 31182061
    [Abstract] [Full Text] [Related]

  • 4. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, Robert C, Marabelle A, Guettier C, Samuel D.
    J Hepatol; 2018 Jun 10; 68(6):1181-1190. PubMed ID: 29427729
    [Abstract] [Full Text] [Related]

  • 5. Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries.
    Ferreira M, Pichon E, Carmier D, Bouquet E, Pageot C, Bejan-Angoulvant T, Campana M, Vermes E, Marchand-Adam S.
    Target Oncol; 2018 Aug 10; 13(4):509-515. PubMed ID: 30006825
    [Abstract] [Full Text] [Related]

  • 6. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V.
    Chest; 2017 Aug 10; 152(2):271-281. PubMed ID: 28499515
    [Abstract] [Full Text] [Related]

  • 7. Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability?
    Marchand L, Reffet S, Dalle S, Disse E, Vouillarmet J, Cugnet-Anceau C, Thivolet C.
    Acta Diabetol; 2019 Mar 10; 56(3):377-378. PubMed ID: 30506459
    [No Abstract] [Full Text] [Related]

  • 8. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE, Menzies AM, Wilmott JS, Kakavand H, Madore J, Guminski A, Liniker E, Kong BY, Cooper AJ, Howle JR, Saw RPM, Jakrot V, Lo S, Thompson JF, Carlino MS, Kefford RF, Long GV, Scolyer RA.
    Clin Cancer Res; 2017 Sep 01; 23(17):5024-5033. PubMed ID: 28512174
    [Abstract] [Full Text] [Related]

  • 9. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C.
    Lancet Oncol; 2018 Sep 01; 19(9):1180-1191. PubMed ID: 30120041
    [Abstract] [Full Text] [Related]

  • 10. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Sep 01; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM, Freeman GJ, McDermott DF.
    Clin Ther; 2015 Apr 01; 37(4):764-82. PubMed ID: 25823918
    [Abstract] [Full Text] [Related]

  • 12. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study.
    Min Lee CK, Li S, Tran DC, Zhu GA, Kim J, Kwong BY, Chang ALS.
    J Am Acad Dermatol; 2018 Dec 01; 79(6):1047-1052. PubMed ID: 29857011
    [Abstract] [Full Text] [Related]

  • 13. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.
    Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS.
    J Am Acad Dermatol; 2018 Dec 01; 79(6):1081-1088. PubMed ID: 30025829
    [Abstract] [Full Text] [Related]

  • 14. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K, Janssens K, Specenier P, Weets I, De Block CEM.
    J Clin Endocrinol Metab; 2018 Sep 01; 103(9):3144-3154. PubMed ID: 29955867
    [Abstract] [Full Text] [Related]

  • 15. PD-1 checkpoint inhibition: Toxicities and management.
    Hahn AW, Gill DM, Agarwal N, Maughan BL.
    Urol Oncol; 2017 Dec 01; 35(12):701-707. PubMed ID: 28889921
    [Abstract] [Full Text] [Related]

  • 16. A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
    Lopez AT, Khanna T, Antonov N, Audrey-Bayan C, Geskin L.
    Int J Dermatol; 2018 Jun 01; 57(6):664-669. PubMed ID: 29630716
    [Abstract] [Full Text] [Related]

  • 17. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
    Scott ES, Long GV, Guminski A, Clifton-Bligh RJ, Menzies AM, Tsang VH.
    Eur J Endocrinol; 2018 Feb 01; 178(2):173-180. PubMed ID: 29187509
    [Abstract] [Full Text] [Related]

  • 18. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
    Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O.
    Lancet Haematol; 2019 Jan 01; 6(1):e48-e57. PubMed ID: 30528137
    [Abstract] [Full Text] [Related]

  • 19. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
    Bellmunt J, Powles T, Vogelzang NJ.
    Cancer Treat Rev; 2017 Mar 01; 54():58-67. PubMed ID: 28214651
    [Abstract] [Full Text] [Related]

  • 20. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M, Xiong G, Cao Z, Yang G, Zheng S, Song X, You L, Zheng L, Zhang T, Zhao Y.
    Cancer Lett; 2017 Oct 28; 407():57-65. PubMed ID: 28826722
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.